| Old Articles: <Older 21061-21070 Newer> |
|---|
 |
The Motley Fool
February 26, 2007
Brian Lawler |
Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways.   |
The Motley Fool
February 26, 2007
Brian Lawler |
Waiting on AtheroGenics The results might be positive for this pharma, but don't bet on it. Investors, take note. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
The Motley Fool
February 26, 2007
Rick Aristotle Munarriz |
From Better to Worse at XM XM's quarterly report doesn't exactly translate to beautiful reception. The planned merger with Sirius should help on several fronts, though regulatory approval appears dicey. Investors, take note. |
The Motley Fool
February 26, 2007
Tim Beyers |
Fool on the Street: Healthy Heinz Apparently, selling health is healthy for business. But organic innovation isn't the most important factor in going global. Investors, take note. |
The Motley Fool
February 26, 2007
Brian Lawler |
Is QLT the Comeback Kid? The Canadian drugmaker updates investors on its outlook for 2007. |
The Motley Fool
February 26, 2007
Alyce Lomax |
Entercom's Costly Quarter Legal issues and other expenses drag down the radio station's profits. If there's one thing Entercom does have going for it, it's the fact that it does return cash to shareholders in the form of a dividend. |
The Motley Fool
February 26, 2007
Tim Beyers |
Marvel's Mostly Mighty: Fool by Numbers The entertainment company released earnings for the 2006 fiscal year: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Checkup... |
The Motley Fool
February 26, 2007
Tim Beyers |
No Ghost in Marvel's Earnings: Fool by Numbers The entertainment company released earnings for the fourth-quarter 2006: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Checkup... |
The Motley Fool
February 26, 2007
Tim Beyers |
Marvel's Still-Uncertain Universe Each quarter is a cliffhanger. Marvel's movie business is more complex than it appears. What investors may not know is how much of a risk Marvel is taking in becoming a studio and what rights it retains. |
| <Older 21061-21070 Newer> Return to current articles. |
